Navigation Links
RA Drugs Linked to Slight Skin Cancer Risk

But the medications' benefits outweigh the downside, experts say

WEDNESDAY, Aug. 29 (HealthDay News) -- People taking rheumatoid arthritis drugs such as etanercept (Enbrel) or infliximab (Remicade) may be at a slightly increased risk for skin cancer, researchers report.

However, the risk is probably not significant enough to outweigh the benefits of these drugs, the researchers said.

These so-called biologic treatments work by blocking tumor necrosis factor alpha (TNF-alpha), which previous studies had found to be linked with increased risk of skin, lung and blood cancers.

"The risk of skin cancer is marginally increased among people with rheumatoid arthritis," said lead researcher Dr. Frederick Wolfe, a clinical professor of internal medicine at the University of Kansas School of Medicine. "But it's nothing that anybody should be worried about," he added.

For the study, Wolfe and his colleagues collected data on 13,001 patients with rheumatoid arthritis included in the National Data Bank for Rheumatic Diseases and the U.S. National Cancer Institute SEER (Surveillance, Epidemiology, and End-Results). The researchers found a total of 623 cases of skin cancer and 537 cases of other cancers.

They also found that anti-TNF-alpha medications were associated with a slight increased risk of skin cancer. But, they did not find any increased risk for other cancers, according to the report in the September issue of Arthritis & Rheumatism.

The heightened risk for skin cancer is very small, Wolfe emphasized. For melanoma, the most serious skin cancer, the increased risk is about two-fold; the actual risk is less than one in a thousand patients, he said.

"This is reassuring data," Wolfe said. "The fact that one didn't find an increased risk for other cancers looks like, in the short term, these drugs are safe," he said.

However, Wolfe noted that continued use of these drugs over the long term could reveal other problems.

One expert agreed that the benefits of TNF-alpha drugs far outweighed the risks to people with rheumatoid arthritis, an autoimmune disease characterized by chronic inflammation of the joints and tissue surrounding vital organs.

"The whole issue of the side effects of these biological agents is so controversial and unclarified," said Christopher Evans, the Robert W. Lovett professor of orthopedic surgery at the Center for Molecular Orthopaedics at Harvard Medical School.

"This study contradicts other studies that suggested greater risks. If the data hold up, I think it's encouraging for patients," he said.

Some patients with rheumatoid arthritis end up crippled, and their life expectancy is shortened, Evans said.

"If I were a severe rheumatoid arthritis patient whose quality of life depended upon these drugs, I'd continue to take them," he said. "The risk of melanoma is less than the risk of leading a shortened, miserable existence."

More information

To learn more about rheumatoid arthritis, visit the Arthritis Foundation.

SOURCES: Frederick Wolfe, M.D., clinical professor of internal medicine, University of Kansas School of Medicine, Kansas City; Christopher Evans, D.Sc., Ph.D., Robert W. Lovett professor of orthopedic surgery, Center for Molecular Orthopaedics, Harvard Medical School, Boston; September 2007, Arthritis & Rheumatism

Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Cancer drugs in development nearly doubled since 1995
5. Cipla holds talks with mining giant to supply AIDS drugs for South African workers
6. African HIV strains more resistant to anti HIV drugs
7. Emphasis to ban Drugs ads by Doctors
8. Right drugs drastically cut stroke risk
9. Osteoporosis Drugs: right time to take-off
10. Drugs disrupt formation of blood vessels
11. Relating heart protection and antihypertensive drugs
Post Your Comments:
(Date:11/26/2015)... Viejo, CA (PRWEB) , ... November 26, 2015 ... ... users a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This ... style options. These classically-influenced trailer titles work with any font, giving users limitless ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... , ... Ministers, senior government and UN agencies, representatives from ... Excellence, and public R&D institutions, civil societies and other partners gathered today at ... Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. The three- day meeting ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Dental professionals who ... Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) ... in Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® ... are aware of the benefits of Botox® in the treatment of moderate facial wrinkling, ... soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
(Date:11/26/2015)... Research and Markets ( ) ... Future Horizons and Growth Strategies in the Japanese ... Segment Forecasts, Competitive Intelligence, Emerging Opportunities" report ... --> This new 247-page report ... drug monitoring market, including emerging tests, technologies, instrumentation, ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
Breaking Medicine Technology: